Respiratory tract infection

Global Immune Health Supplements Market Trends Analysis Report 2021-2028, By Product, Form, Application, Mode Of Medication and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Friday, October 22, 2021
Fitness & Nutrition, Health, Pharmacy, Vitamin, Fungus, Infection, Mineral, USD, Herbal, COPD, Application, Virus, Adoption, Urinary tract infection, Zinc, Respiratory tract infection, Risk, Immunity, Vitamin C, Council, COVID-19, CAGR, Dietary supplement, Bacteria, Awareness, Parasitism, Immune system, Degenerative disease, Market share, Council for Responsible Nutrition, Population, CRN, Prevalence, Probiotic, Asthma, Form

The "Immune Health Supplements Market Size, Share & Trends Analysis Report By Product, By Form, By Application, By Mode Of Medication, By Distribution Channel, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immune Health Supplements Market Size, Share & Trends Analysis Report By Product, By Form, By Application, By Mode Of Medication, By Distribution Channel, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global immune health supplements market size is expected to reach USD 132.0 billion by 2028.
  • However, taking dietary supplements among individuals for immune health has been increased from 27 percent to 32 percent from 2019 to 2020.
  • Global Immune Health Supplements Market Variables, Trends & Scope

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults

Retrieved on: 
Wednesday, September 29, 2021
Mortality, Regulation of tobacco by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, European Directive on Traditional Herbal Medicinal Products, Vaccine, Safety, Urinary tract infection, Food, Behavior, European Medicines Agency, Health, Infection, Pulmonary hypertension, Janssen, Adult, Disease, Heart, Season, Medicine, Respiratory syncytial virus, Janssen Pharmaceuticals, Science, Bronchitis, RSV, Medication, Clinical trial, Risk, Annual report, Committee, New and Emerging Respiratory Virus Threats Advisory Group, U.S. Securities and Exchange Commission, Ageing, LLC, Johnson & Johnson, National Institute, Bronchiolitis, Security (finance), Patient, Committee for Medicinal Products for Human Use, Johnson & Johnson COVID-19 vaccine, Respiratory tract infection, COVID-19, Pneumonia, Research, Metabolism, Pharmaceutical industry

"With no vaccine or broadly-indicated antiviral treatment available, preventive solutions to address the significant morbidity and mortality in older adults caused by RSV have long been an unmet need."

Key Points: 
  • "With no vaccine or broadly-indicated antiviral treatment available, preventive solutions to address the significant morbidity and mortality in older adults caused by RSV have long been an unmet need."
  • Respiratory syncytial virus (RSV) is a prevalent, highly contagious respiratory virus and a leading cause of bronchitis, bronchiolitis and pneumonia, affecting more than 64 million people worldwide in a typical year.
  • Between 3-7 percent of older adults (age 60 and older) and 4-10 percent of high-risk adults (age 18 and older) experience RSV in a typical year.
  • Trial participants will be randomized to receive either one dose of active investigational vaccine or placebo.

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

Retrieved on: 
Monday, September 20, 2021
Food, Infection, Goal, Harvard Medical School, PCR, Ministry, Curve, Internet meme, Â, Combat, Lancet, Solution, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pediatrics, Hospital, FDA, Patient, Defense, AMR, Boston Children's Hospital, Physician, MD, Maimonides Medical Center, PLOS One, Division, CEO, Child, Respiratory tract infection, European Journal of Clinical Microbiology & Infectious Diseases, Technology, European Commission, Fever, CE marking, Degenerative disease, Emergency medicine, Genetically modified bacteria, Virus, Host response to cancer therapy, CRP, Protein, Vaccine

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective.

Key Points: 
  • Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective.
  • The novelty of MeMeds technology is that it decodes the bodys immune response to infection, the host response, rather than focusing on detecting the presence of a microbe.
  • MeMed Key is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need.
  • The MeMed Key development program has been partially funded by the US Department of Defense and the EU Commission.

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

Retrieved on: 
Monday, September 20, 2021
Food, Infection, Goal, Harvard Medical School, PCR, Ministry, Curve, Internet meme, Â, Combat, Lancet, Solution, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pediatrics, Hospital, FDA, Patient, Defense, AMR, Boston Children's Hospital, Physician, MD, Maimonides Medical Center, PLOS One, Division, CEO, Child, Respiratory tract infection, European Journal of Clinical Microbiology & Infectious Diseases, Technology, European Commission, Fever, CE marking, Degenerative disease, Emergency medicine, Genetically modified bacteria, Virus, Host response to cancer therapy, CRP, Protein, Vaccine

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective.

Key Points: 
  • Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective.
  • The novelty of MeMeds technology is that it decodes the bodys immune response to infection, the host response, rather than focusing on detecting the presence of a microbe.
  • MeMed Key is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need.
  • The MeMed Key development program has been partially funded by the US Department of Defense and the EU Commission.

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Retrieved on: 
Tuesday, May 18, 2021
Respiratory diseases, Medical specialties, Clinical medicine, Respiratory therapy, Infectious diseases, Pneumonia, Ventilator-associated pneumonia, Bronchiectasis, Ventilator, Sputum, Respiratory tract infection, COVID-19

The ABT measures bacterial load in suspected respiratory infections and may represent an effective alternative to sputum culture-based diagnostics.

Key Points: 
  • The ABT measures bacterial load in suspected respiratory infections and may represent an effective alternative to sputum culture-based diagnostics.
  • Approximately 25% of the 1.7 million intensive care unit (ICU) patients who are on ventilators each year develop VAP.
  • The non-radioactive, isotopic ratio of 13CO2/12CO2 in the exhaled breath of the patient is measured by the Avisa spectrometer.
  • Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year.

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021

Retrieved on: 
Thursday, May 13, 2021
Medical specialties, Branches of biology, Clinical medicine, Infectious diseases, Bacterial diseases, Bacteriology, Nontuberculous mycobacteria, Lung, Tuberculosis, Respiratory tract infection, Severe acute respiratory syndrome, Respiratory tract

Beyond Air is currently advancing its revolutionary LungFit\xc2\xae for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).

Key Points: 
  • Beyond Air is currently advancing its revolutionary LungFit\xc2\xae for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.
  • LungFit\xc2\xae can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g.

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

Retrieved on: 
Thursday, April 8, 2021
Technology, Medical devices, Women, Software, Biotechnology, Health, Consumer, General Health, Data management, Articles, Life sciences, Branches of biology, Infectious diseases, Amplifiers, Biotechnology, Molecular biology, Polymerase chain reaction, Respiratory tract infection, Antimicrobial resistance, Infection

This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.

Key Points: 
  • This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.
  • Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
  • Mobidiag generated approximately $42 million (35 million) of revenue in calendar 2020.

Elder Berry Adulteration Documented by New Botanical Adulterants Prevention Program Article

Retrieved on: 
Tuesday, March 23, 2021
Medical specialties, Clinical medicine, Infectious diseases, Medicine, Dietary supplement, BAPP, Common cold, Adulterant, Respiratory tract infection, Upper respiratory tract infection

Dietary supplements containing elder berry are widely used medicinally to treat symptoms of upper respiratory infections associated with colds and flus.

Key Points: 
  • Dietary supplements containing elder berry are widely used medicinally to treat symptoms of upper respiratory infections associated with colds and flus.
  • The elder berry adulteration article is the 64th peer-reviewed publication by BAPP, all of which are available for free access on the BAPP site .
  • To date, BAPP has published 64 peer-reviewed documents, including Botanical Adulterants Prevention Bulletins, Laboratory Guidance Documents, Botanical Adulterants Monitor e-newsletters, and others.
  • As with all of the programs publications, this review of elder berry adulteration is freely accessible on the programs website (registration required).

5th Annual Infection Control, Sterilization & Decontamination Conference: Two Day Online Conference - March 25th-26th, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 25, 2021
Health, Other Health, Medical specialties, Infectious diseases, Health, Epidemiology, Healthcare-associated infections, Infection prevention and control, Hospital-acquired infection, Infection, Sterilization, Urinary tract infection, Respiratory tract infection

The "5th Annual Infection Control, Sterilization & Decontamination Virtual Conference (GMT)" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5th Annual Infection Control, Sterilization & Decontamination Virtual Conference (GMT)" conference has been added to ResearchAndMarkets.com's offering.
  • Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has a healthcare-associated infection (HAIs).
  • Most of the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection, and urinary tract infection.
  • The 5th Annual Infection Control, Sterilization, and Decontamination in Healthcare Virtual Conference, scheduled for 25th & 26th March 2021, aiming at providing platform to experts from hospitals, academia, and government institutions discussing the innovations, challenges, and future aspects of infection control, decontamination, and sterilization.

Global Respiratory Infection Diagnostic Markets Report 2021-2025 with COVID-19 Impact, Forecasting/Analysis & Executive and Consultant Guides

Retrieved on: 
Wednesday, January 27, 2021
Medical specialties, Clinical medicine, Medicine, Respiratory diseases, Coronavirus disease, Occupational safety and health, Zoonoses, Common cold, Respiratory tract infection

DUBLIN, Jan. 27, 2021 /PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 27, 2021 /PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress.
  • COVID-19 has broken open the market for point of care testing of respiratory infections.
  • The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous.